Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Doctors can prescribe Mounjaro off-label for weight loss, but the drug does not have FDA approval for this use. Tirzepatide is FDA-approved for weight loss as the brand-name drug Zepbound.

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...

With off-label use, doctors prescribe a drug for ... For a cost comparison of Ozempic versus Wegovy or Mounjaro versus Zepbound, talk with your doctor or insurance provider. You can also check ...

We could point out that tirzepatide, the active ingredient in Mounjaro and Zepbound, is still undergoing many clinical trials and should earn key label expansions. Last year, the medicine aced a ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.